Mechanisms of statin-induced myalgia assessed by physiogenomic associations

Atherosclerosis

Volumn 218, Issue 2, 2011, Pages 451-456

  Ruaño, Gualberto ^a,b   Windemuth, Andreas ^a,b   Wu, Alan H B ^c   Kane, John P ^d   Malloy, Mary J ^d   Pullinger, Clive R ^d   Kocherla, Mohan ^b   Bogaard, Kali ^b   Gordon, Bruce R ^e   Holford, Theodore R ^f   Gupta, Ankur ^a   Seip, Richard L ^a   Thompson, Paul D ^a  

^a HARTFORD HOSPITAL   (United States)

^b Genomas Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ROGOSIN INSTITUTE   (United States)

^f YALE UNIVERSITY   (United States)

Author keywords

Dyslipidemia; Myalgia; Myopathy; Personalized medicine; Pharmacogenetics; Physiogenomics; Statins

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MYOTONIC DYSTROPHY PROTEIN KINASE; PARA HYDROXYBENZOATE POLYPRENYLTRANSFERASE; PRAVASTATIN; PROTEIN ATP2B1; PROTEIN KINASE; ROSUVASTATIN; SIMVASTATIN; TRANSFERASE; UBIDECARENONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; CALCIUM HOMEOSTASIS; CHILD; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GENETIC VARIATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MUSCULAR DISEASES; PHARMACOGENETICS;

EID: 84860404559     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.007     Document Type: Article

References (27)

1. Findlay S. The statin drugs. Prescription and price trends October 2005 to December 2006 and potential cost savings to Medicare from increased use of lower cost statins. Consumer Reports 2007.
2. Statins The World Market, 2009-2024. 3-3-2009. London, UK: Visiongain, Ltd.
3. Waters D.D. What the statin trials have taught us. Am J Cardiol 2006, 98:129-134.
4. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA 2003, 289:1681-1690.
5. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414.
6. Ghatak A., Faheem O., Thompson P.D. The genetics of statin-induced myopathy. Atherosclerosis 2010, 210:337-343.
7. Ruaño G., Thompson P.D., Windemuth A., et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 2005, 6:865-872.
8. Ruaño G., Thompson P.D., Windemuth A., et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007, 36:329-335.
9. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359:789-799.
10. Ruaño G., Windemuth A., Holford T., Physiogenomics Integrating Systems Engineering and Nanotechnology for Personalized Medicine. The biomedical engineering handbook 2005, CRC Press, 28-1-28-9. 3rd ed. J.D. Bronzino (Ed.).
11. Vladutiu G.D. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008, 20:648-655.
12. Forsgren M., Attersand A., Lake S., et al. Isolation and functional expression of human COQ2, a gene encoding a polyprenyl transferase involved in the synthesis of CoQ. Biochem J 2004, 382:519-526.
13. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231-2237.
14. Oh J., Ban M.R., Miskie B.A., Pollex R.L., Hegele R.A. Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.
15. Westwood F.R., Bigley A., Randall K., Marsden A.M., Scott R.C. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005, 33:246-257.
16. Caso G., Kelly P., McNurlan M.A., Lawson W.E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.
17. Young J.M., Florkowski C.M., Molyneux S.L., et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007, 100:1400-1403.
18. Baker S.K., Tarnopolsky M.A. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001, 24:258-272.
19. Mosieniak G., Figiel I., Kaminska B., Cyclosporin A. an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J Neurochem 1997, 68:1142-1149.
20. Draeger A., Monastyrskaya K., Mohaupt M., et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006, 210:94-102.
21. Musova Z., Mazanec R., Krepelova A., et al. Highly unstable sequence interruptions of the CTG repeat in the myotonic dystrophy gene. Am J Med Genet A 2009, 149A:1365-1374.
22. McKusick V.A. Mendelian inheritance in man and its online version, OMIM. Am J Hum Genet 2007, 80:588-604.
23. Voora D., Shah S.H., Spasojevic I., et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616.
24. Wilke R.A., Mareedu R.K., Moore J.H. The pathway less traveled: moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scale pharmacogenetic association studies. Curr Pharmacogenomics Person Med 2008, 6:150-159.
25. Seip R.L., Duconge J., Ruaño G. Genotype-guided statin therapy. Pharmacogenomic testing in current clinical practice: implementation in the clinical laboratory 2010, 155-174. Humana Press, Springer Science+Business Media, New York. A.H.B. Wu, J. Yeo (Eds.).
26. Winkelmann B.R., Herrington D. Pharmacogenomics-10 years of progress: a cardiovascular perspective. Pharmacogenomics 2010, 11:613-616.
27. Pasternak R.C., Smith S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002, 33:2337-2341.